Absci Corporation will present at multiple healthcare conferences and host investor meetings in November 2025.
Quiver AI Summary
Absci Corporation, a clinical-stage biotech company utilizing generative AI for drug development, announced its participation in several upcoming investor conferences. This includes a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on November 10, 1x1 meetings at the UBS Global Healthcare Conference on November 11, and a presentation at the Jefferies Global Healthcare Conference on November 18, where they will also host additional 1x1 meetings. The company emphasizes its innovative Integrated Drug Creation™ platform that combines AI and synthetic biology to rapidly develop new therapeutics, including treatments for inflammatory bowel disease and hair regrowth. Interested parties can access live and archived webcasts of the presentations on Absci's investor relations website.
Potential Positives
- Absci Corporation is actively participating in multiple prestigious investor conferences, which could enhance visibility and attract potential investors.
- The company's innovative approach to drug discovery using generative AI positions it at the forefront of biotechnology, highlighting its potential for growth and relevance in the industry.
- Absci has a promising pipeline of therapeutics, including potentially best-in-class treatments for inflammatory bowel disease and groundbreaking innovations in hair regrowth, demonstrating its commitment to addressing significant medical needs.
Potential Negatives
- Absci's participation in multiple investor conferences may indicate a need for increased visibility and support in a competitive market, suggesting challenges in gaining investor confidence.
- The absence of specific updates on clinical trial results or progress regarding their therapeutics could lead to uncertainties among investors about the company's advancements and future prospects.
- While presenting at multiple conferences, the focus on their pipeline products may imply that the company needs to boost interest and engagement in its ongoing research and developments.
FAQ
What investor conferences is Absci Corporation participating in?
Absci Corporation is participating in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, UBS Global Healthcare Conference, and Jefferies Global Healthcare Conference.
When is Absci's fireside chat scheduled?
The fireside chat will take place on Monday, November 10 at 10:00 a.m. Eastern Time.
How can I access Absci's conference webcasts?
Live and archived webcasts of the conferences can be accessed at the company’s investor relations website at investors.absci.com.
What innovative therapeutics is Absci developing?
Absci is developing ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth in androgenetic alopecia.
Where is Absci headquartered?
Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center in Switzerland.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ABSI Insider Trading Activity
$ABSI insiders have traded $ABSI stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
- MENELAS N PANGALOS purchased 95,785 shares for an estimated $254,788
- ANDREAS BUSCH (Chief Innovation Officer) purchased 50,000 shares for an estimated $152,000
- TODD BEDRICK (SVP, CAO) purchased 10,000 shares for an estimated $27,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ABSI Hedge Fund Activity
We have seen 69 institutional investors add shares of $ABSI stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 1,763,909 shares (+37.6%) to their portfolio in Q2 2025, for an estimated $4,533,246
- BLACKROCK, INC. added 1,576,757 shares (+23.2%) to their portfolio in Q2 2025, for an estimated $4,052,265
- WOODLINE PARTNERS LP added 1,574,861 shares (+113.2%) to their portfolio in Q2 2025, for an estimated $4,047,392
- CITADEL ADVISORS LLC removed 953,579 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,450,698
- ARK INVESTMENT MANAGEMENT LLC removed 909,161 shares (-8.3%) from their portfolio in Q2 2025, for an estimated $2,336,543
- MILLENNIUM MANAGEMENT LLC removed 845,167 shares (-78.6%) from their portfolio in Q2 2025, for an estimated $2,172,079
- FMR LLC added 747,004 shares (+4.1%) to their portfolio in Q2 2025, for an estimated $1,919,800
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ABSI Analyst Ratings
Wall Street analysts have issued reports on $ABSI in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 10/02/2025
- Needham issued a "Buy" rating on 08/13/2025
- Morgan Stanley issued a "Overweight" rating on 07/28/2025
To track analyst ratings and price targets for $ABSI, check out Quiver Quantitative's $ABSI forecast page.
$ABSI Price Targets
Multiple analysts have issued price targets for $ABSI recently. We have seen 2 analysts offer price targets for $ABSI in the last 6 months, with a median target of $6.945.
Here are some recent targets:
- Vikram Purohit from Morgan Stanley set a target price of $5.89 on 08/18/2025
- Gil Blum from Needham set a target price of $8.0 on 08/13/2025
Full Release
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:
-
Guggenheim Securities 2
nd
Annual Healthcare Innovation Conference (Boston, MA)
Fireside chat on Monday, November 10 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings
-
UBS Global Healthcare Conference (Palm Beach Gardens, FL)
Hosting 1x1 meetings on Tuesday, November 11
-
Jefferies Global Healthcare Conference (London, UK)
Presentation on Tuesday, November 18 at 9:30 a.m. Greenwich Mean Time / 4:30 a.m. Eastern Time, and hosting 1x1 meetings
Interested parties may access live and archived webcasts of the Guggenheim and Jefferies fireside chat and presentation sessions on the company’s investor relations website at investors.absci.com .
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn ( @absci ), X ( @Abscibio ) and YouTube .
Investor Contact
Alex Khan
VP, Finance & Investor Relations
[email protected]
Media Contact
[email protected]
